|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
F17464, a dopamine D3 receptor antagonist with relatively high D3 selectivity (70 fold vs D2 in vitro), exhibits an antipsychotic profile in preclinical studies, and therapeutic efficacy was demonstrated in a randomized placebo-controlled clinical trial in patients with schizophrenia (Bitter et al.
|
31773210 |
2020 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?
|
31765822 |
2020 |
|
Hyperprolactinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genetic variants in cytochrome P450 (CYP) (CYP2D6), dopamine receptor (DRD2, DRD3) and serotonin receptor (HTR2A, HTR2C) genes were previously associated with antipsychotic-induced hyperprolactinaemia.
|
31520576 |
2020 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings may help to improve the understanding of the relationship between 5-HT2A and DRD3 genotypes and schizophrenia pathogenesis.
|
31813806 |
2019 |
|
Mental Depression
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
The Association between DRD3 Ser9Gly Polymorphism and Depression Severity in Parkinson's Disease.
|
31143436 |
2019 |
|
Mental Depression
|
0.370 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to examine the role of DRD3 in the anxiety-like and depression-like behavioral changes induced by estrogen and progesterone.
|
30292827 |
2019 |
|
Depressive disorder
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
The Association between DRD3 Ser9Gly Polymorphism and Depression Severity in Parkinson's Disease.
|
31143436 |
2019 |
|
Depressive disorder
|
0.360 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to examine the role of DRD3 in the anxiety-like and depression-like behavioral changes induced by estrogen and progesterone.
|
30292827 |
2019 |
|
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This means that the minority of markers found in patients-decreased concentration of L-3,4-dihydroxyphenylalanine (L-DOPA) and dihydroxyphenylacetic acid (DOPAC) and increased dopamine D3 receptor gene expression-are specific for preclinical-prodromal stage and are suitable for early diagnosis of PD.
|
30128652 |
2019 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Then, two-way analysis of covariance (ANCOVA) was applied to investigate main effects and interactions of PD and DRD3 Ser9Gly polymorphism on the brain function via amplitude of low-frequency fluctuations (ALFF) approach.
|
31143436 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we evaluated the therapeutic potential of targeting DRD3 confined to CD4<sup>+</sup> T-cells by inducing the pharmacologic antagonism or the transcriptional inhibition of DRD3-signalling in a mouse model of PD induced by the chronic administration of MPTP and probenecid (MPTPp).
|
31118938 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous results indicated that pharmacologic-antagonism or genetic deficiency of dopamine receptor D3 (DRD3) attenuated neuroinflammation and neurodegeneration in two mouse models of PD.
|
31810491 |
2019 |
|
Tardive Dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that upregulation of putamen dopamine D3 receptor and alterations along the noncanonical GRK6/β-arrestin2/Akt/GSK-3β molecular cascade are associated with the development of tardive dyskinesia in nonhuman primates.
|
30675935 |
2019 |
|
Drug-induced tardive dyskinesia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that upregulation of putamen dopamine D3 receptor and alterations along the noncanonical GRK6/β-arrestin2/Akt/GSK-3β molecular cascade are associated with the development of tardive dyskinesia in nonhuman primates.
|
30675935 |
2019 |
|
Depressed mood
|
0.060 |
GeneticVariation
|
phenotype |
BEFREE |
The Association between DRD3 Ser9Gly Polymorphism and Depression Severity in Parkinson's Disease.
|
31143436 |
2019 |
|
Depressed mood
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The aim of the present study was to examine the role of DRD3 in the anxiety-like and depression-like behavioral changes induced by estrogen and progesterone.
|
30292827 |
2019 |
|
Abnormal behavior
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The aim of the present study was to examine the role of DRD3 in the anxiety-like and depression-like behavioral changes induced by estrogen and progesterone.
|
30292827 |
2019 |
|
Anxiety Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
The aim of the present study was to examine the role of DRD3 in the anxiety-like and depression-like behavioral changes induced by estrogen and progesterone.
|
30292827 |
2019 |
|
Impulsive Behavior
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
DRD3 and COMT variants were not associated with these DD and impulsivity outcomes.
|
31192519 |
2019 |
|
Substance Use Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
There has been considerable interest in the development of dopamine D3 receptor (DRD<sub>3</sub>) partial agonists and antagonists for the treatment of substance use disorders.
|
30659274 |
2019 |
|
Anxiety
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to examine the role of DRD3 in the anxiety-like and depression-like behavioral changes induced by estrogen and progesterone.
|
30292827 |
2019 |
|
Chondrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In competing-risks regression analysis, differentiation (<i>P</i> = 0.005), metastasis (<i>P</i> = 0.014), invasion (<i>P</i> = 0.028), AJCC stage (<i>P</i> = 0.003), Enneking stage (<i>P</i> = 0.036), and DAXX (<i>P</i> = 0.039), and DRD3(<i>P</i> = 0.019) expression were independent predictors of death from chondrosarcoma.
|
31850367 |
2019 |
|
Hallucinations, Visual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Multiple Poisson regression analyses showed that individuals carrying the DRD3 Ser/Ser and Ser/Gly genotypes presented increased prevalence ratios of visual hallucinations (9.7-fold and 4.4-fold, respectively; P < .001).
|
30794329 |
2019 |
|
Prodromal Stage
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
This means that the minority of markers found in patients-decreased concentration of L-3,4-dihydroxyphenylalanine (L-DOPA) and dihydroxyphenylacetic acid (DOPAC) and increased dopamine D3 receptor gene expression-are specific for preclinical-prodromal stage and are suitable for early diagnosis of PD.
|
30128652 |
2019 |
|
Sporadic Parkinson disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
|
31119645 |
2019 |